Protagonist Therapeutics Inc (PTGX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.55B
Last updated: Nov 17, 2026 at 4:33 PM ET
Protagonist Therapeutics Inc (PTGX) Stock Chart
Protagonist Therapeutics (PTGX) has a latest price of $124.67 on Nov 17, 2026, 22.5% below its 52-week high of $160.81. Its price rose 47.3% over the past 12 months. The month-end price rose 670.5% over the 10 years through Oct 2026, a compound annual rate of 22.7%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $147.75 in Aug 2026 and its lowest $6.47 in Nov 2018, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart PTGX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for PTGX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 19.5%, and over 6 months it rose 26.7%. The month-end price rose 896.2% over the 3 years through Oct 2026, a compound annual rate of 115.2%.
| Period | Change |
|---|---|
| 1 month | -7.3% |
| 3 months | -19.5% |
| 6 months | +26.7% |
| 12 months | +47.3% |
| 12 months, with dividends | +47.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +896.2% | +115.2% |
| 5 years | +364.9% | +36.0% |
| 10 years | +670.5% | +22.7% |
Price by Year
Its best calendar year was 2020, when the price rose 186.0%, and its weakest was 2022, when it fell 68.1%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $144.85 | +65.8% |
| 2025 | $87.34 | +126.3% |
| 2024 | $38.60 | +68.3% |
| 2023 | $22.93 | +110.2% |
| 2022 | $10.91 | -68.1% |
| 2021 | $34.20 | +69.6% |
| 2020 | $20.16 | +186.0% |
| 2019 | $7.05 | +4.8% |
| 2018 | $6.73 | -67.6% |
| 2017 | $20.80 | -5.4% |
Trading Range
The price is 10.6% below its 50-day average of $139.46 and 4.1% above its 200-day average of $119.71.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $124.67 | |
| 52-week high | $160.81 | -22.5% |
| 52-week low | $77.00 | +61.9% |
| 50-day average | $139.46 | -10.6% |
| 200-day average | $119.71 | +4.1% |
Price Risk
Over 3 years, its largest fall from a peak was 31.6%.
| Measure | Value |
|---|---|
| 1-year beta | 0.94 |
| Largest fall, 1 year | -21.4% |
| Largest fall, 3 years | -31.6% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About PTGX
What is PTGX's 1-year price change?
Protagonist Therapeutics's price rose 47.3% over the past 12 months. With dividends included, the 12-month total return was 47.3%.
What is PTGX's 5-year price change?
Protagonist Therapeutics's month-end price rose 364.9% over the 5 years through Oct 2026, a compound annual rate of 36.0%. These figures leave out dividends.
What is PTGX's 52-week high and low?
Protagonist Therapeutics's 52-week high is $160.81 and its 52-week low is $77.00. Its latest price of $124.67 on Nov 17, 2026 is 22.5% below the high.
What is PTGX's beta?
Protagonist Therapeutics's 1-year beta against the S&P 500 is 0.94, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 21.4%.
Is the PTGX chart free?
Yes. Advanced Charting for PTGX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
PTGX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors